Altasciences Wins 2025 CDMO Award for Small Molecule Dosage
Altasciences, a nine-time recipient of the prestigious CRO Leadership Award, proudly announces its latest achievement: the 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This recognition highlights Altasciences’ unwavering commitment to excellence in contract development and manufacturing, as well as its continued dedication to supporting pharmaceutical and biotech companies in bringing innovative therapies to patients worldwide.
Altasciences’ contract development and manufacturing organization (CDMO) site offers a comprehensive range of services that facilitate drug development from early discovery to commercialization. The facility, inspected and approved by the U.S. Food and Drug Administration (FDA), is equipped with Grade C cleanrooms, research and development (R&D) and analytical laboratories, International Council for Harmonisation (ICH) stability chambers, and a current Good Manufacturing Practice (cGMP) warehouse. These resources ensure the highest quality standards are met throughout the drug development process.
“This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” said Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are grateful for the opportunity to partner with esteemed sponsors from around the globe, providing them with integrated solutions that not only support groundbreaking therapeutic progress but also contribute meaningfully to getting those therapies to those who need them, faster.”
Altasciences specializes in small molecule dosage form development, providing end-to-end solutions for drug sponsors seeking a reliable and innovative partner. The company’s expertise spans a broad range of pharmaceutical dosage forms, including but not limited to tablets, liquid- and powder-filled capsules, over-encapsulated capsules, nanomilled suspensions, creams, gels, powders, and terminally sterilized injectables. By leveraging cutting-edge technology and scientific expertise, Altasciences is able to customize and optimize drug formulations to meet the unique needs of each client and regulatory requirement.
For 14 years, Outsourced Pharma’s CDMO Leadership Awards have served as an industry benchmark for excellence, recognizing the top-performing contract development and manufacturing organizations based on extensive industry research and direct sponsor feedback. The awards are designed to highlight organizations that consistently deliver superior service, innovation, and quality in pharmaceutical development and manufacturing.
“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” said Louis Garguilo, Chief Editor at Outsourced Pharma. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs.”
Altasciences’ CDMO facility is designed to support all phases of drug development, ensuring a seamless transition from early-phase formulation to late-stage scale-up and commercial manufacturing. The company maintains a robust quality control system that includes in-house analytical testing and environmental monitoring to guarantee batch consistency and regulatory compliance. By integrating these services under one roof, Altasciences streamlines the formulation, manufacturing, and analytical processes, ultimately accelerating the timeline from preclinical development to clinical trials and commercial production.
What sets Altasciences apart in the competitive CDMO landscape is its commitment to collaboration and innovation. The company works closely with clients to develop tailored solutions that align with project goals, regulatory requirements, and market needs. Through strategic partnerships and continuous investment in advanced manufacturing technologies, Altasciences ensures that drug sponsors have access to the most efficient and effective pathways to commercialization.
Moreover, Altasciences places a strong emphasis on sustainability and operational efficiency. The company is dedicated to implementing environmentally responsible practices across its facilities, including energy-efficient equipment, waste reduction initiatives, and sustainable sourcing of raw materials. This commitment not only aligns with global efforts to reduce the pharmaceutical industry’s environmental footprint but also contributes to cost savings and enhanced operational efficiencies for clients.
As the pharmaceutical landscape continues to evolve, Altasciences remains at the forefront of innovation, adapting to emerging industry trends and regulatory changes. With a team of highly skilled scientists, engineers, and regulatory experts, the company is well-positioned to address the complex challenges of modern drug development. Whether optimizing formulation strategies, enhancing bioavailability, or navigating regulatory approvals, Altasciences provides the expertise and infrastructure necessary to support successful drug development programs.
The 2025 CDMO Leadership Award serves as a testament to Altasciences’ dedication to quality, innovation, and client satisfaction. As the company continues to expand its capabilities and global reach, it remains committed to its mission of accelerating drug development and delivering life-changing therapies to patients in need.
